ReviewMediators of inflammation2016
Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces.
Review in Mediators of inflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review.Journal of Crohn's & colitis · 2022Pooled it
- Milk polar lipids favorably alter circulating and intestinal ceramide and sphingomyelin species in postmenopausal women.JCI insight · 2021Trial
- Investigating the Impact of Aspartame on Ulcerative Colitis Through Network Toxicology and Molecular Docking.Food science & nutrition · 2025Article
- Therapeutic potential of mesenchymal stem cell-derived extracellular vesicles: A focus on inflammatory bowel disease.Clinical and translational medicine · 2024Review
- Mechanisms of Action of Exclusive Enteral Nutrition and Other Nutritional Therapies in Crohn's Disease.Nutrients · 2024Review
- The manganese transporter SLC39A8 links alkaline ceramidase 1 to inflammatory bowel disease.Nature communications · 2024Article
- Ganglioside GD3 Regulates Inflammation and Epithelial-to-Mesenchymal Transition in Human Nasal Epithelial Cells.International journal of molecular sciences · 2024Article
- Short-Term Clinical Response and Changes in the Fecal Microbiota and Metabolite Levels in Patients with Crohn's Disease After Stem Cell Infusions.Stem cells translational medicine · 2023Article
- Article
- Oxidative Stress, Inflammation, Gut Dysbiosis: What Can Polyphenols Do in Inflammatory Bowel Disease?Antioxidants (Basel, Switzerland) · 2023Review
- Alteration of the gut microbiota after surgery in preterm infants with necrotizing enterocolitis.Frontiers in pediatrics · 2023Article
- Therapeutic Mechanism of Baicalin in Experimental Colitis Analyzed Using Network Pharmacology and Metabolomics.Drug design, development and therapy · 2023Article
- The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis.United European gastroenterology journal · 2022Review
- Single sample pathway analysis in metabolomics: performance evaluation and application.BMC bioinformatics · 2022Article
- Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota.Stem cell research & therapy · 2022Article
- Microscopic Colitis Patients Possess a Perturbed and Inflammatory Gut Microbiota.Digestive diseases and sciences · 2022Article
- A Preliminary Metabolomic Study of Yorkshire Terrier Enteropathy.Metabolites · 2022Article
- Bile Acid Signaling in Inflammatory Bowel Disease.International journal of molecular sciences · 2021Review
- What We Know So Far about the Metabolite-Mediated Microbiota-Intestinal Immunity Dialogue and How to Hear the Sound of This Crosstalk.Metabolites · 2021Review
- MiMeNet: Exploring microbiome-metabolome relationships using neural networks.PLoS computational biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complex sphingolipids are essential structural components of intestinal membranes, providing protection and integrity to the intestinal mucosa and regulating intestinal absorption processes. The role of sphingolipid signaling has been established in numerous cellular events, including intestinal cell survival, growth, differentiation, and apoptosis. A significant body of knowledge demonstrates that intestinal sphingolipids play a crucial role, as such and through their signaling pathways, in immunity and inflammatory disorders. In this review, we report on and discuss the current knowledge on the metabolism, signaling, and functional implications of sphingolipids in inflammatory bowel disease (IBD), focusing on the different aspects of sphingolipid actions on inflammatory responses and on the potential of sphingolipid-targeted molecules as anti-IBD therapeutic agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.